Cargando…

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer

New therapeutic developments aimed at treating women with advanced breast cancer currently focus both on identifying patients eligible for targeted therapeutic concepts and on the continuing development of immune therapies. The data on CDK4/6 inhibitors are now complete and consistent in this class...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Volkmar, Wöckel, Achim, Lux, Michael P., Janni, Wolfgang, Hartkopf, Andreas D., Nabieva, Naiba, Taran, Florin-Andrei, Hadji, Peyman, Tesch, Hans, Ettl, Johannes, Lüftner, Diana, Welslau, Manfred, Belleville, Erik, Brucker, Sara Y., Schütz, Florian, Fasching, Peter A., Fehm, Tanja N., Kolberg, Hans-Christian, Schneeweiss, Andreas, Overkamp, Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255740/ https://www.ncbi.nlm.nih.gov/pubmed/30498279 http://dx.doi.org/10.1055/a-0715-2899

Ejemplares similares

Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
por: Wöckel, Achim, et al.
Publicado: (2018)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
por: Janni, Wolfgang, et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
por: Taran, Florin-Andrei, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
por: Tesch, Hans, et al.
Publicado: (2020)

Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
por: Lüftner, Diana, et al.
Publicado: (2020)

Update Breast Cancer 2020 Part 3 – Early Breast Cancer
por: Huober, Jens, et al.
Publicado: (2020)

Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

Correction: Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
por: Lux, Michael P., et al.
Publicado: (2021)

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
por: Aktas, Bahriye, et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2022)

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Update Breast Cancer 2021 Part 4 – Prevention and Early Stages
por: Thomssen, Christoph, et al.
Publicado: (2022)

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
por: Lux, Michael P., et al.
Publicado: (2023)

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer
por: Hartkopf, Andreas D., et al.
Publicado: (2023)

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
por: Kolberg, Hans-Christian, et al.
Publicado: (2023)

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2022)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2023)

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2023)

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2022)

Return of individual genomic research results within the PRAEGNANT multicenter registry study
por: Huebner, Hanna, et al.
Publicado: (2022)

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages
por: Stickeler, Elmar, et al.
Publicado: (2021)

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
por: Engler, Tobias, et al.
Publicado: (2022)

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
por: Ditsch, Nina, et al.
Publicado: (2021)

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel
por: Fehm, Tanja N., et al.
Publicado: (2021)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians
por: Gass, Paul, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rr8e5k2jt1h5rnhvo5o0jjpu54